Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of ruxolitinib versus best available therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation
MOH_2017-01-29_000043Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Novartis. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on MOH_2017-01-29_000043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-29_000043.